If Successful, HRA Pharma Acquisition Will Complete Perrigo’s Pivot Towards Self-Care
Executive Summary
If its acquisition of France's HRA Pharma completes, Perrigo will have “enough growth in our back pocket for the next three to five years without making any further acquisitions,” says the firm’s UK & Ireland chief, Neil Lister, in an exclusive interview with HBW Insight.
You may also be interested in...
HRA Proposes OTC Norgestrel Birth Control
HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.
HBW Insight’s Key Takeaways From 2021: #1 Join The Self-Care Movement
The first year of the pandemic saw a move among consumers towards prevention and wellness under the banner of "self-care". In 2021, the "self-care movement" really started to gain momentum as these new healthcare habits endured, and companies responded with more wellness options, in some cases even pivoting towards becoming pure self-care players.
Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19
Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.